OBJECTIVES: Iron deficiency (ID) and iron deficiency anaemia (IDA) are serious co-morbidities that arise in several clinical situations and have significant health impacts. It amplifies underlying chronic conditions increasing the risk of hospitalisations, cost of the disease management and increase risk of mortality. Oral iron is mostly the first line treatment for iron deficiency, however it sometimes cannot be tolerated due to its side effects, responds relatively slowly, or cannot be used in certain chronic conditions. Intravenous iron demonstrated the trends to reduce transfusion needs, lower mortality risk, and shorter hospital stay. [1] [2] [3] The objective of the study was to estimate the direct healthcare costs of available intravenous iron in Singapore; ferric carboxymaltose (FCM), iron sucrose (IS) and blood transfusion for patients with IDA in Singapore. The assessment was made from the third party perspective represented by the Department of Medicine,  National University Hospital Singapore. METHODS: A cost-minimisation analysis compared 1000mg FCM (1 visit, 15 minutes per visit) versus IS (5 visits, 60 minutes per visit) versus the current practice of 2 units of blood transfusion followed by oral administration for 3-6 months. The cost was based on the average daily hospitalisation costs from the institution. RESULTS: The utilisation of FCM increased administration efficiency and optimised healthcare resources by reducing the number of consultation visits, time to administer 1000mg of iron, and the average amount required to correct IDA. Administering the most cost-efficient option was estimated to save the healthcare system SGD1022 per patient (FCM vs blood transfusion). CONCLUSIONS: A single dose of 1,000mg FCM is more cost-efficient than IS, blood transfusion only, and blood transfusion combined with oral iron for the treatment of IDA in Singapore.